. . . "Does the receptor, spectrum of G proteins and the role of GABA-B system change during development"@en . "1"^^ . . . . "0"^^ . . "http://www.isvav.cz/projectDetail.do?rowId=GA309/99/0207"^^ . . . "Projekt si kladl za c\u00EDl vy\u0159e\u0161it, zda se m\u011Bn\u00ED receptor, spektrum G protein\u016F a \u00FAloha GABA-B syst\u00E9mu b\u011Bhem ontogeneze. Auto\u0159i zjistili, \u017Ee \u00FAloha GABA-B syst\u00E9mu je z\u00E1visl\u00E1 zejm\u00E9na na typu z\u00E1chvatu (p\u0159i \u0159e\u0161en\u00ED vyu\u017Eili model myoklonick\u00FDch k\u0159e\u010D\u00ED a absenc\u00ED). Vys"@cs . . "5"^^ . "GA309/99/0207" . "Inhibition mediated by GABAB system might play an important role not only in adult but also in immature brain. Unfortunately, there are only a few developmental physiological data, some information about GABAB receptors but nothing on the development of G proteins, related to GABAB receptors. The aim of our study is to compare GABAB receptors (their K and Bmax), spectrum of G proteins (especially Gi/Go and Gs proteins) and electrophysiological actions (evoked responses and potentiation and depression phenomena) of GABAB agonist and antagonist at certain levels of rat brain maturation. Experiments will be focused on cerebral cortex, thalamus, and hippocampus, i.e. those structures where GABAB system is markedly represented. In the second part of the project, GABAB system will be influenced by repeated administrations of an agonist baclofen or an antagonist SCH 50911 at two different stages of maturation chosen on the basis of data on development of GABAB receptors. The same mea"@en . "5"^^ . "Neuvedeno."@en . "M\u011Bn\u00ED se receptor, spektrum G protein\u016F a \u00FAloha GABA-B syst\u00E9mu b\u011Bhem ontogeneze ?" . . . . . . . "0"^^ . "2003-04-01+02:00"^^ . "Inhibice zprost\u0159edkovan\u00E1 GABAb syst\u00E9mem je z\u0159ejm\u011B v\u00FDznamn\u00E1 nejenom ve zral\u00E9m, ale i ve vyv\u00EDjej\u00EDc\u00EDm se mozku. Bohu\u017Eel existuj\u00ED jen ojedin\u011Bl\u00E1 data fyziologick\u00E1 a o GABAb receptorech, ale zcela chyb\u011Bj\u00ED \u00FAdaje o G proteinech, spojen\u00FDch s GABAb receptory. C\u00EDlem t\u00E9to studie je korelovat GABAb receptory (jejich KD a Bmax), spektrum G protein\u016F (zvl\u00E1\u0161t\u011B GI/Go a Gs protein\u016F a elektrofyziologick\u00FDch \u00FA\u010Dink\u016F (evokovan\u00E9 potenci\u00E1ly a jejich potenciace a deprese) GABAb agonisty a antagonisty na \u0161esti stadi\u00EDch v\u00FDvoje mozku potkana. Pokusy budou zam\u011B\u0159eny na mozkovou k\u016Fru, thalamus a hipokampus, tedy struktury, kde je v\u00FDrazn\u00E9 zastoupen\u00ED GABAb syst\u00E9mu. Ve druh\u00E9 \u010D\u00E1sti pokus\u016F budeme ovliv\u0148ovat GABAb syst\u00E9m opakovan\u00FDm pod\u00E1v\u00E1n\u00EDm agonisty baklofenu nebo antagonisty SCH 50911na dvou r\u016Fzn\u00FDch \u00FArovn\u00EDch v\u00FDvoje, zvolen\u00FDch na z\u00E1klad\u011B \u00FAdajk\u016F o v\u00FDvoji GABAb receptor\u016F. Budeme p\u0159i tom sledovat stejn\u00E9 ukazatele jako v prvn\u00ED \u010D\u00E1sti." .